Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: Stroke. 2013 May 14;44(6):1525–1531. doi: 10.1161/STROKEAHA.113.001116

Figure 1.

Figure 1

Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.